NEW YORK (GenomeWeb News) – McKinley Scientific and New Objective today announced a co-marketing and development deal for the expansion of applications for liquid chromatography-mass spectrometry systems.

Sparta, NJ-based McKinley will provide financing and support services for mass spectrometry, while Woburn, Mass.-based New Objective is providing its nanospray front end technologies. Together, the firms will co-market their products and develop distribution and services to deliver mass spec solutions, they said.

Further financial and other details were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

This Week in Nucleic Acids Research: Researchers describe a new method to find large-scale structural variants in cancer genomes, a glimpse at an approach for profiling miRNAs in tumor samples from TCGA, and more.

Intellia Therapeutics has raised $70 million, becoming the latest firm leveraging the gene editing technology to haul in a gob of cash.

Now going beyond reporting fetal aneuploidies, NIPTs may be providing too much information that may be useless, some doctors and genetic counselor say.

A group of organizations in the UK say that there needs to be discussions about the use of technologies such as CRISPR/Cas-9 for human germline editing.